▶ 調査レポート

世界の流行性脳脊髄膜炎ワクチン市場2023年:企業・地域・種類・用途別分析

• 英文タイトル:Global Epidemic Cerebrospinal Meningitis Vaccines Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

GlobalInfoResearchが調査・発行した産業分析レポートです。世界の流行性脳脊髄膜炎ワクチン市場2023年:企業・地域・種類・用途別分析 / Global Epidemic Cerebrospinal Meningitis Vaccines Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029 / MRC309Z7846資料のイメージです。• レポートコード:MRC309Z7846
• 出版社/出版日:GlobalInfoResearch / 2023年9月
• レポート形態:英文、PDF、90ページ
• 納品方法:Eメール(2-3営業日)
• 産業分類:医薬品&ヘルスケア
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
GlobalInfoResearchの最新の調査によると、世界の流行性脳脊髄膜炎ワクチンの市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx%の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界の流行性脳脊髄膜炎ワクチン市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本レポートの主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- 流行性脳脊髄膜炎ワクチンの成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

流行性脳脊髄膜炎ワクチン市場は種類と用途によって区分されます。2018年~2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメント
・グループA及びグループC髄膜炎菌多糖体ワクチン、グループA及びグループC髄膜炎菌複合体ワクチン、グループACYW135髄膜炎菌多糖体ワクチン、グループACYW135髄膜炎菌複合体ワクチン、グループA髄膜炎菌多糖体ワクチン、グループB髄膜炎菌ワクチン

用途別セグメント
・1歳以下、1歳以上

主要な市場プレーヤー
・Pfizer、Sanofi Pasteur、GSK、Hulan Bio、Lanzhou Institute of Biological Products、Tianyuan biology、Walvax、Zhifei

地域別セグメントは次の地域・国をカバーします。
・北米(米国、カナダ、メキシコ)
・ヨーロッパ(ドイツ、フランス、イギリス、ロシア、イタリア)
・アジア太平洋(日本、中国、韓国、インド、東南アジア、オーストラリア)
・南アメリカ(ブラジル、アルゼンチン、コロンビア)
・中東およびアフリカ(サウジアラビア、UAE、エジプト、南アフリカ)

本調査レポートの内容は計15章あります。
・第1章では、流行性脳脊髄膜炎ワクチン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な流行性脳脊髄膜炎ワクチンメーカーの企業概要、2019年~2022年までの流行性脳脊髄膜炎ワクチンの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な流行性脳脊髄膜炎ワクチンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年~2029年までの地域別流行性脳脊髄膜炎ワクチンの販売量、売上、成長性を示しています。
・第5、6章では、2018年~2029年までの流行性脳脊髄膜炎ワクチンの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年~2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年~2029年までの主要地域での流行性脳脊髄膜炎ワクチン市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および流行性脳脊髄膜炎ワクチンの産業チェーンを掲載しています。
・第14、15章では、流行性脳脊髄膜炎ワクチンの販売チャネル、販売業者、顧客、調査結果について説明します。

***** 目次(一部) *****

・市場概要
- 流行性脳脊髄膜炎ワクチンの概要
- 種類別分析(2018年vs2022年vs2029年):グループA及びグループC髄膜炎菌多糖体ワクチン、グループA及びグループC髄膜炎菌複合体ワクチン、グループACYW135髄膜炎菌多糖体ワクチン、グループACYW135髄膜炎菌複合体ワクチン、グループA髄膜炎菌多糖体ワクチン、グループB髄膜炎菌ワクチン
- 用途別分析(2018年vs2022年vs2029年):1歳以下、1歳以上
- 世界の流行性脳脊髄膜炎ワクチン市場規模・予測
- 世界の流行性脳脊髄膜炎ワクチン生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報(企業概要、製品概要、販売量、価格、売上)
- Pfizer、Sanofi Pasteur、GSK、Hulan Bio、Lanzhou Institute of Biological Products、Tianyuan biology、Walvax、Zhifei
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年:グループA及びグループC髄膜炎菌多糖体ワクチン、グループA及びグループC髄膜炎菌複合体ワクチン、グループACYW135髄膜炎菌多糖体ワクチン、グループACYW135髄膜炎菌複合体ワクチン、グループA髄膜炎菌多糖体ワクチン、グループB髄膜炎菌ワクチン
・用途別分析2018年-2029年:1歳以下、1歳以上
・流行性脳脊髄膜炎ワクチンの北米市場
- 種類別市場規模2018年-2029年
- 用途別市場規模2018年-2029年
- 主要国別市場規模:アメリカ、カナダ、メキシコなど
・流行性脳脊髄膜炎ワクチンのヨーロッパ市場
- 種類別市場規模2018年-2029年
- 用途別市場規模2018年-2029年
- 主要国別市場規模:ドイツ、イギリス、フランス、ロシア、イタリアなど
・流行性脳脊髄膜炎ワクチンのアジア市場
- 種類別市場規模2018年-2029年
- 用途別市場規模2018年-2029年
- 主要国別市場規模:中国、日本、韓国、インド、東南アジア、オーストラリアなど
・流行性脳脊髄膜炎ワクチンの南米市場
- 種類別市場規模2018年-2029年
- 用途別市場規模2018年-2029年
- 主要国別市場規模:ブラジル、アルゼンチンなど
・流行性脳脊髄膜炎ワクチンの中東・アフリカ市場
- 種類別市場規模2018年-2029年
- 用途別市場規模2018年-2029年
- 主要国別市場規模:サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学(成長要因、阻害要因、トレンド、ポーターズファイブフォース分析)
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

According to our (Global Info Research) latest study, the global Epidemic Cerebrospinal Meningitis Vaccines market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
Vaccines can help prevent meningococcal disease, which is any type of illness caused by Neisseria meningitidis bacteria.
The Global Info Research report includes an overview of the development of the Epidemic Cerebrospinal Meningitis Vaccines industry chain, the market status of Under 1 Year Old (Group A and Group C Meningococcal Polysaccharide Vaccine, Group A and Group C Meningococcal Conjugate Vaccine), 1 Year Old and Above (Group A and Group C Meningococcal Polysaccharide Vaccine, Group A and Group C Meningococcal Conjugate Vaccine), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Epidemic Cerebrospinal Meningitis Vaccines.
Regionally, the report analyzes the Epidemic Cerebrospinal Meningitis Vaccines markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Epidemic Cerebrospinal Meningitis Vaccines market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Epidemic Cerebrospinal Meningitis Vaccines market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Epidemic Cerebrospinal Meningitis Vaccines industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Group A and Group C Meningococcal Polysaccharide Vaccine, Group A and Group C Meningococcal Conjugate Vaccine).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Epidemic Cerebrospinal Meningitis Vaccines market.
Regional Analysis: The report involves examining the Epidemic Cerebrospinal Meningitis Vaccines market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Epidemic Cerebrospinal Meningitis Vaccines market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Epidemic Cerebrospinal Meningitis Vaccines:
Company Analysis: Report covers individual Epidemic Cerebrospinal Meningitis Vaccines manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Epidemic Cerebrospinal Meningitis Vaccines This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Under 1 Year Old, 1 Year Old and Above).
Technology Analysis: Report covers specific technologies relevant to Epidemic Cerebrospinal Meningitis Vaccines. It assesses the current state, advancements, and potential future developments in Epidemic Cerebrospinal Meningitis Vaccines areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Epidemic Cerebrospinal Meningitis Vaccines market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Epidemic Cerebrospinal Meningitis Vaccines market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Group A and Group C Meningococcal Polysaccharide Vaccine
Group A and Group C Meningococcal Conjugate Vaccine
Group ACYW135 Meningococcal Polysaccharide Vaccine
Group ACYW135 Meningococcal Conjugate Vaccine
Group A Meningococcal Polysaccharide Vaccine
Mmeningococcal Group B Vaccine
Market segment by Application
Under 1 Year Old
1 Year Old and Above
Major players covered
Pfizer
Sanofi Pasteur
GSK
Hulan Bio
Lanzhou Institute of Biological Products
Tianyuan biology
Walvax
Zhifei
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Epidemic Cerebrospinal Meningitis Vaccines product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Epidemic Cerebrospinal Meningitis Vaccines, with price, sales, revenue and global market share of Epidemic Cerebrospinal Meningitis Vaccines from 2018 to 2023.
Chapter 3, the Epidemic Cerebrospinal Meningitis Vaccines competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Epidemic Cerebrospinal Meningitis Vaccines breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Epidemic Cerebrospinal Meningitis Vaccines market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Epidemic Cerebrospinal Meningitis Vaccines.
Chapter 14 and 15, to describe Epidemic Cerebrospinal Meningitis Vaccines sales channel, distributors, customers, research findings and conclusion.

レポート目次

1 Market Overview
1.1 Product Overview and Scope of Epidemic Cerebrospinal Meningitis Vaccines
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Epidemic Cerebrospinal Meningitis Vaccines Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Group A and Group C Meningococcal Polysaccharide Vaccine
1.3.3 Group A and Group C Meningococcal Conjugate Vaccine
1.3.4 Group ACYW135 Meningococcal Polysaccharide Vaccine
1.3.5 Group ACYW135 Meningococcal Conjugate Vaccine
1.3.6 Group A Meningococcal Polysaccharide Vaccine
1.3.7 Mmeningococcal Group B Vaccine
1.4 Market Analysis by Application
1.4.1 Overview: Global Epidemic Cerebrospinal Meningitis Vaccines Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Under 1 Year Old
1.4.3 1 Year Old and Above
1.5 Global Epidemic Cerebrospinal Meningitis Vaccines Market Size & Forecast
1.5.1 Global Epidemic Cerebrospinal Meningitis Vaccines Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity (2018-2029)
1.5.3 Global Epidemic Cerebrospinal Meningitis Vaccines Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Epidemic Cerebrospinal Meningitis Vaccines Product and Services
2.1.4 Pfizer Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Pfizer Recent Developments/Updates
2.2 Sanofi Pasteur
2.2.1 Sanofi Pasteur Details
2.2.2 Sanofi Pasteur Major Business
2.2.3 Sanofi Pasteur Epidemic Cerebrospinal Meningitis Vaccines Product and Services
2.2.4 Sanofi Pasteur Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Sanofi Pasteur Recent Developments/Updates
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Epidemic Cerebrospinal Meningitis Vaccines Product and Services
2.3.4 GSK Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 GSK Recent Developments/Updates
2.4 Hulan Bio
2.4.1 Hulan Bio Details
2.4.2 Hulan Bio Major Business
2.4.3 Hulan Bio Epidemic Cerebrospinal Meningitis Vaccines Product and Services
2.4.4 Hulan Bio Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Hulan Bio Recent Developments/Updates
2.5 Lanzhou Institute of Biological Products
2.5.1 Lanzhou Institute of Biological Products Details
2.5.2 Lanzhou Institute of Biological Products Major Business
2.5.3 Lanzhou Institute of Biological Products Epidemic Cerebrospinal Meningitis Vaccines Product and Services
2.5.4 Lanzhou Institute of Biological Products Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Lanzhou Institute of Biological Products Recent Developments/Updates
2.6 Tianyuan biology
2.6.1 Tianyuan biology Details
2.6.2 Tianyuan biology Major Business
2.6.3 Tianyuan biology Epidemic Cerebrospinal Meningitis Vaccines Product and Services
2.6.4 Tianyuan biology Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Tianyuan biology Recent Developments/Updates
2.7 Walvax
2.7.1 Walvax Details
2.7.2 Walvax Major Business
2.7.3 Walvax Epidemic Cerebrospinal Meningitis Vaccines Product and Services
2.7.4 Walvax Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Walvax Recent Developments/Updates
2.8 Zhifei
2.8.1 Zhifei Details
2.8.2 Zhifei Major Business
2.8.3 Zhifei Epidemic Cerebrospinal Meningitis Vaccines Product and Services
2.8.4 Zhifei Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Zhifei Recent Developments/Updates
3 Competitive Environment: Epidemic Cerebrospinal Meningitis Vaccines by Manufacturer
3.1 Global Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Manufacturer (2018-2023)
3.2 Global Epidemic Cerebrospinal Meningitis Vaccines Revenue by Manufacturer (2018-2023)
3.3 Global Epidemic Cerebrospinal Meningitis Vaccines Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Epidemic Cerebrospinal Meningitis Vaccines by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Epidemic Cerebrospinal Meningitis Vaccines Manufacturer Market Share in 2022
3.4.2 Top 6 Epidemic Cerebrospinal Meningitis Vaccines Manufacturer Market Share in 2022
3.5 Epidemic Cerebrospinal Meningitis Vaccines Market: Overall Company Footprint Analysis
3.5.1 Epidemic Cerebrospinal Meningitis Vaccines Market: Region Footprint
3.5.2 Epidemic Cerebrospinal Meningitis Vaccines Market: Company Product Type Footprint
3.5.3 Epidemic Cerebrospinal Meningitis Vaccines Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Epidemic Cerebrospinal Meningitis Vaccines Market Size by Region
4.1.1 Global Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Region (2018-2029)
4.1.2 Global Epidemic Cerebrospinal Meningitis Vaccines Consumption Value by Region (2018-2029)
4.1.3 Global Epidemic Cerebrospinal Meningitis Vaccines Average Price by Region (2018-2029)
4.2 North America Epidemic Cerebrospinal Meningitis Vaccines Consumption Value (2018-2029)
4.3 Europe Epidemic Cerebrospinal Meningitis Vaccines Consumption Value (2018-2029)
4.4 Asia-Pacific Epidemic Cerebrospinal Meningitis Vaccines Consumption Value (2018-2029)
4.5 South America Epidemic Cerebrospinal Meningitis Vaccines Consumption Value (2018-2029)
4.6 Middle East and Africa Epidemic Cerebrospinal Meningitis Vaccines Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Type (2018-2029)
5.2 Global Epidemic Cerebrospinal Meningitis Vaccines Consumption Value by Type (2018-2029)
5.3 Global Epidemic Cerebrospinal Meningitis Vaccines Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Application (2018-2029)
6.2 Global Epidemic Cerebrospinal Meningitis Vaccines Consumption Value by Application (2018-2029)
6.3 Global Epidemic Cerebrospinal Meningitis Vaccines Average Price by Application (2018-2029)
7 North America
7.1 North America Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Type (2018-2029)
7.2 North America Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Application (2018-2029)
7.3 North America Epidemic Cerebrospinal Meningitis Vaccines Market Size by Country
7.3.1 North America Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Country (2018-2029)
7.3.2 North America Epidemic Cerebrospinal Meningitis Vaccines Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Type (2018-2029)
8.2 Europe Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Application (2018-2029)
8.3 Europe Epidemic Cerebrospinal Meningitis Vaccines Market Size by Country
8.3.1 Europe Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Country (2018-2029)
8.3.2 Europe Epidemic Cerebrospinal Meningitis Vaccines Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Epidemic Cerebrospinal Meningitis Vaccines Market Size by Region
9.3.1 Asia-Pacific Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Epidemic Cerebrospinal Meningitis Vaccines Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Type (2018-2029)
10.2 South America Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Application (2018-2029)
10.3 South America Epidemic Cerebrospinal Meningitis Vaccines Market Size by Country
10.3.1 South America Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Country (2018-2029)
10.3.2 South America Epidemic Cerebrospinal Meningitis Vaccines Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Epidemic Cerebrospinal Meningitis Vaccines Market Size by Country
11.3.1 Middle East & Africa Epidemic Cerebrospinal Meningitis Vaccines Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Epidemic Cerebrospinal Meningitis Vaccines Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Epidemic Cerebrospinal Meningitis Vaccines Market Drivers
12.2 Epidemic Cerebrospinal Meningitis Vaccines Market Restraints
12.3 Epidemic Cerebrospinal Meningitis Vaccines Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Epidemic Cerebrospinal Meningitis Vaccines and Key Manufacturers
13.2 Manufacturing Costs Percentage of Epidemic Cerebrospinal Meningitis Vaccines
13.3 Epidemic Cerebrospinal Meningitis Vaccines Production Process
13.4 Epidemic Cerebrospinal Meningitis Vaccines Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Epidemic Cerebrospinal Meningitis Vaccines Typical Distributors
14.3 Epidemic Cerebrospinal Meningitis Vaccines Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer